Skip to main content English


Christopher Adlbrecht
Priv.-Doz. Dr. Christopher Adlbrecht, MBA, FHFA, FESCSelf employed Cardiologist & external lecturer PhD-program Endocrinology and Metabolism

Department of Medicine II
Position: Lecturer


Coronary Artery Disease; Heart Failure

Research interests

  • Heart Failure: Prognosis, Medical Therapy;
  • Coronary Heart Disease: Coronary Intervention, Medical Therapy

Techniques, methods & infrastructure

  • Translational Research
  • Clinical Trials


  • HypoNETtical Connections – HYPOxic ischemic brain injury and Neutrophil Extracellular Traps Induced by Cardiac Arrest (2019)
    Source of Funding: Medical Scientific Fund of the Mayor of the City of Vienna, Research Grant of the Medical-Scientific Fund of the Mayor of Vienna #19061
    Principal Investigator
  • Proteomische Analyse zur Suche nach neuen progn. Markern für das neurolog. Ergebnis nach Reanimation (2014)
    Source of Funding: OeNB (Oesterreichische Nationalbank), Anniversary Fund
    Principal Investigator

Selected publications

  1. Adlbrecht, C. et al., 2020. Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial. Critical Care, 24(1). Available at:
  2. Adlbrecht, C. et al., 2014. Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. International Journal of Cardiology, 174(1), pp.90-95. Available at:
  3. Adlbrecht, C. et al., 2014. Peri-interventional endothelin-A receptor blockade improves long-term outcome in patients with ST-elevation acute myocardial infarction. Thrombosis and Haemostasis, 112(1), pp.176-182. Available at:
  4. Mark, D.B. et al., 2009. Quality of Life after Late Invasive Therapy for Occluded Arteries. N Engl J Med, 360(8), pp.774-783. Available at:
  5. Adlbrecht, C. et al., 2008. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body�s red cell volume. European Heart Journal, 29(19), pp.2343-2350. Available at: